NCT04617483View on ClinicalTrials.gov

Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

1,040

Participants

Timeline

Start Date

October 31, 2020

Primary Completion Date

November 28, 2020

Study Completion Date

May 31, 2021

Conditions
Covid19
Interventions
BIOLOGICAL

Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14

The antigen content of the commercial scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group 26-45.

BIOLOGICAL

Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14

The antigen content of the pilot scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group 18-59.

BIOLOGICAL

Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly

The antigen content of the pilot scale inactivated SARS-CoV-2 vaccine was 600SU/0.5ml, vaccinated in the age group above 60.

Trial Locations (1)

224100

Dafeng District Center for Disease Prevention and Control, Yancheng

All Listed Sponsors
lead

Sinovac Research and Development Co., Ltd.

INDUSTRY

NCT04617483 - Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults | Biotech Hunter | Biotech Hunter